about
The evolution of poxvirus vaccinesA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenKinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizationsDistinct p21 requirements for regulating normal and self-reactive T cells through IFN-γ production.Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein BoostHead-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesPotential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensDeletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells.Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciSuppression of NYVAC Infection in HeLa Cells Requires RNase L but Is Independent of Protein Kinase R Activity.A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression.Activation of the double-stranded RNA-dependent protein kinase PKR by small ubiquitin-like modifier (SUMO).Novel insights on the progression of intermediate viral forms in the morphogenesis of vaccinia virus.Neutrophil and vaccine.
P50
Q26995905-C65F1166-C74A-425E-A7FC-58523E8A0E2DQ27302081-1EBF5F32-76CD-4DA0-9954-215F4C136E1FQ34593874-542D446A-D9C0-47CE-87C8-EA6551A39D30Q34877991-D41EDAF9-72CC-4809-8961-CF3C1CBE1CABQ34991112-3B465D22-2F50-4DCA-B442-2212CF83BFF6Q35038794-BB7A877C-EF75-4ABF-B12E-ACE1B430A66BQ35212666-5463E2E5-0CFC-4AAD-9A54-5F51FDA3F0F7Q35488175-26E22B3E-FF14-41B0-B062-3E3DEE78EC58Q35760486-1CF78024-B856-4C2B-90F2-3CF903D938D9Q35914311-890835E7-BCCB-4615-9706-357D0C1BC787Q36736400-14AE2AD5-ED2D-4232-B3DB-8C109506B980Q37643731-B63431C2-3129-4369-ACFE-21BE5B472F9BQ37643733-21095F8D-A596-459A-AACC-A17E1C06D3C9Q37711813-4DB89B21-ED86-4C67-B75C-DAF48C4BBFA0Q40120388-D52F7C68-E3B5-435B-BA7D-C7259A7BDD6CQ40235609-8CC43BBD-181C-436A-924E-677935C7FF38Q40290590-C1713E60-F029-4C7E-A6B8-78708EC95E42Q40339467-3AAF293D-9405-456F-8E3E-6AC66DA4DEC2Q40875488-EE411143-7551-43DA-B191-6A3F72E979EFQ40919787-81F1B52B-F87B-44BE-91F7-6F6CDF6F02D8Q41739971-360D9097-7E2C-4B0B-BF4E-51BE48F9C2C5Q42203018-B4635987-D1DD-4EF5-AB8A-81AC55C7693BQ42240765-554AE0C8-B86A-47AC-9257-5C45AB051451Q43211131-263032C8-40C1-404E-B48A-27738DF82D68
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0003-0846-2827
@en
name
Mariano Esteban
@ast
Mariano Esteban
@en
Mariano Esteban
@es
Mariano Esteban
@nl
type
label
Mariano Esteban
@ast
Mariano Esteban
@en
Mariano Esteban
@es
Mariano Esteban
@nl
prefLabel
Mariano Esteban
@ast
Mariano Esteban
@en
Mariano Esteban
@es
Mariano Esteban
@nl
P106
P21
P31
P496
0000-0003-0846-2827